Enjoy the latest cell therapy industry news below, summarized as of August 9th, 2024. [Read more…]
Regenerative Stem Cell Therapy as Treatment for Neck Pain
Neck pain is one of the most pervasive problems in the world today. At any given time, 10 percent of adults report a stiff neck, while X-rays show signs of osteoarthritis in as much as 50 percent of the population over 50. As though that wasn’t enough, 40 percent of males and almost 30 percent of females in the mid-50s and 60s exhibit problems with discs, the round cushioning devices that separate vertebrae. Needless to say, treatment for neck pain is a serious need.
While it doesn’t constitute a deadly disease, neck pain does have the power to negatively impact a person’s life every single day. It makes mobility challenging, hampers daily activities, dampens the pleasure of human touch or hugs, and generally reduces the quality of life. Up until now, medical approaches have included chiropractic care, heating and icing, over-the-counter medication use and surgery. As a rule, those solutions are either too limited or too extreme.
Now there’s a new treatment for neck pain in town: stem cells. These “master cells” have the ability to transform into bodily structures that otherwise would not rebuild, renew, and heal. This offers a very promising neck pain treatment. But what is it? And how does it work?
In this article:
Interview with Accellta’s Intellectual Property (IP) Officer, Eran Cohen
This is an follow-up to our interview with Accellta’s CEO, Dr. Itzchak Angel, who highlighted Accellta’s unique technologies for enabling large scale growth of cells in suspension. This interview features insights from Eran Cohen, Accellta’s head of business development and intellectual property (IP) officer.
NMDP BioTherapies and the NMDP BioTherapies Cord Blood Bank Alliance Introduce Optimal Cord Blood Units for Manufacture of NK Cell Therapies And Other Cord Derived Cell Therapies
Leveraging the Power of the NMDP BioTherapies Cord Blood Bank Alliance, Readily Accessible Cord Blood Units That Meet the Criteria Established in Marin, et al in Nature Medicine for Production of CAR-NK Cells
MINNEAPOLIS, July 18, 2024 — NMDP BioTherapiesSM (formerly known as the Be The Match BioTherapies), a leader in cell and gene therapy development support, and the NMDP BioTherapies Cord Blood Bank Alliance (CBBA), a partnership between NMDP BioTherapies and nine public cord blood banks, are making available pre-identified cord blood units that are optimized for manufacture of cord-derived cell therapies, and in particular cord-derived NK cell therapies. The identification and supply of these units leverages the over 200,000 cord blood units in the inventory of the CBBA as well as NMDP BioTherapies’ cord unit search platform, through which individual cord blood units that meet specific requirements can be rapidly identified. [Read more…]
Astellas, Universal Cells, and Osaka University to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy
Collaborative Research on Innovative Cartilage Organoid Cell Therapy for Intervertebral Disc Degenerative Disease using Astellas’ Universal Donor Cell Technology.
TOKYO and OSAKA, Japan, July 22, 2024 — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura) and Graduate School of Medicine / Faculty of Medicine, Osaka University (President: Shojiro Nishio) announced that Astellas Institute for Regenerative Medicine (a wholly owned subsidiary of Astellas, “AIRM”), Universal Cells (a wholly owned subsidiary of Astellas) and Osaka University have entered into a research collaboration to develop innovative pluripotent stem cell*1-derived cartilage organoid cell therapy for the treatment of intervertebral disc degenerative disease*2. [Read more…]
- « Previous Page
- 1
- …
- 94
- 95
- 96
- 97
- 98
- …
- 338
- Next Page »




